6.4.6. hormonal therapy relapsing patients. panel conducted sr including studies published 2000 onwards . conflicting results found clinical effectiveness ht previous curative therapy primary tumour. studies reported favourable effect ht, including rct addressing research question review (86% vs. 79% advantage os early ht group) . studies find differences early vs. delayed, no, ht. one study found unfavourable effect ht . may result selecting clinically unfavourable cases (early) ht intensive diagnostic workup follow-up patients. studied population highly heterogeneous regarding tumour biology therefore clinical course. predictive factors poor outcomes short psa-dt, high isup grade group, high psa, increased age comorbidities. studies, boorjian, et al., study , high-risk patients, mainly defined high isup grade group short psa-dt (most often less six months) seem benefit (early) ht, especially men long life expectancy. non-steroidal anti-androgens claimed inferior compared castration, difference seen m0 patients . one included rcts suggested intermittent ht inferior continuous ht terms os css . small advantage found qol domains overall qol outcomes. important limitation rct lack stratifying criteria psa-dt initial risk factors. based lack definitive efficacy undoubtedly associated significant side effects, patients recurrence primary curative therapy receive standard ht since minority progress metastases pca-related death. objective ht improve os, postpone distant metastases, improve qol. biochemical response ht holds clinical benefit patient. older patients comorbidities side effects ht may even decrease life expectancy; particular cardiovascular risk factors need considered . early ht reserved highest risk disease progression defined mainly short psa-dt relapse(< 6–12 months) high initial isup grade group (> 2/3) long life expectancy. three-arm randomised phase iii trial (embark) looked patients prostate cancer high-risk biochemical recurrence defined psa-dt ≤9 months psa level ≥2 ng/ml nadir radiation therapy ≥1 ng/ml radical prostatectomy without postoperative radiation therapy . patients randomly assigned 1:1:1 receive enzalutamide daily plus leuprolide every 12 weeks (combination group), placebo plus leuprolide (leuprolide-alone group), enzalutamide monotherapy (monotherapy group). primary end point mfs, combination group compared leuprolide- alone group. mfs monotherapy group compared leuprolide-alone group key secondary endpoint. total 1068 patients randomised. median follow-up 60.7 months, five year - mfs 87.3% (95% ci, 83.0 - 90.6) combination group, 71.4% (95% ci, 65.7 - 76.3) leuprolide-alone group, 80.0% (95% ci, 75.0 - 84.1) monotherapy group. combination enzalutamide plus leuprolide superior leuprolide alone regards mfs (hr 0.42; 95% ci, 0.30 - 0.61; p<0.001). enzalutamide monotherapy also showed superior mfs compared leuprolide alone (hr 0.63; 95% ci, 0.46 - 0.87; p = 0.005). results led fda approval enzalutamide alone combination adt patients high-risk biochemical recurrence november 2023 . time mfs analysis, os data immature 12% deaths overall population. also, intermittent treatment approach considered. enzalutamide treatment suspended psa undetectable (< 0.2 ng/ml) 36 weeks therapy. treatment may reinitiated psa increased ≥ 2.0 ng/ml patients prior radical prostatectomy ≥ 5.0 ng/ml patients prior primary radiation therapy. new safety signals. note, median follow-up five years, overall percentage patients fractures 14% .